http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CZ-2016491-A3
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fece74aa8c0cb73d997c194165159cc |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-12 |
filingDate | 2016-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ba7317d9395f8f71ac987873462e20b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e7b49f0d3b699f137bbde8d07547249 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86777193b54fdfa7dd09ea33fc0759d8 |
publicationDate | 2018-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CZ-2016491-A3 |
titleOfInvention | Process for the preparation of 5-amino-4- (1-cyclopropylnaphthalen-4-yl) -4H-1,2,4-triazole-3-thiol, key intermediate for the production of 2- (5-bromo-4- (1-cyclopropylnaphthalene-4) -yl) -4H-1,2,4-triazol-3-ylthio) acetic acid lesinurad |
abstract | The present invention relates to an improved process for the preparation of a highly pure 5-amino-4- (1-cyclopropylnaphthalen-4-yl) -4-1,2,4-triazole-3-thiol intermediate of formula I, a key intermediate in the production of 2- (5- of bromo-4- (1-cyclopropyl-naphthalen-4-yl) -4-1,2,4-triazol-3-ylthio) acetic acid of formula II known under the generic name lesinurad. A highly pure intermediate is prepared by reacting 4-cyclopropyl-1-naphthylisothiocyanate with a suitable S-alkylthiosemicarbazide in a suitable solvent. Lesinurad is a selective uric acid transport inhibitor that lowers blood uric acid levels. It is used in combination with some of the drugs acting as xanthine oxidase inhibitors in patients who are not satisfactorily treated with xanthine oxidase inhibitors alone. |
priorityDate | 2016-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 94.